Work

Safety signals with Nintedanib: Case series exploring the adverse effects of Nintedanib in interstitial lung disease

Year: 2025

Type: article

Abstract: Nintedanib, a Tyrosine Kinase Inhibitor (TKI) with antifibrotic properties, has been approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF), chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype and systemic sclerosis- associated ILD (SSc -ILD). Gastrointestinal (GI) adverse effects and Transaminitis were reported commonly with its use. This case series narrates the clinical experiences of patients treated with Nintedanib and highlights the role of Nintedanib in ILD management while emphasizing the need for careful monitoring to optimize safety and treatment outcomes.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.17556393

Authors: Gopika, G, Kodiattu, Sara Kurien, Harikrishnan, S, R S, Jacob Jesurun

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7104435811

FWCI:

Cites:

Cited by:

Related to: